Two different starting points

BPC-157 and TB-500 are often discussed together, but they come from unrelated lines of investigation. One is a short synthetic pentadecapeptide described in work on a gastric juice protein fraction. The other corresponds to an actin-binding fragment of a much larger intracellular protein. Their proposed mechanisms are not interchangeable, and neither should be read as a variant of the other.

BPC-157: sequence and origin

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV. It was first described in research on a gastric juice protein fraction, and the early literature is therefore gastrointestinal in orientation. Later in vitro and animal work extended the questions into endothelial, fibroblast and connective tissue contexts. The sequence is stable and readily handled in standard laboratory conditions, which is part of why it appears so frequently in experimental protocols.

TB-500 and the actin-binding fragment

TB-500 corresponds to the actin-binding region of thymosin beta 4, given as the short sequence Ac-LKKTETQ. Its documented biology centres on actin sequestration and cell migration rather than on any single receptor target. Actin monomer binding changes the availability of actin for polymerisation, and migration assays are the natural place to look for consequences of that change in a controlled system.

In vitro readouts in the published work

Cell work in this field is fairly consistent in what it measures:

• fibroblast migration in scratch and transwell formats;
• fibroblast and keratinocyte proliferation, usually by a colorimetric or thymidine based assay;
• endothelial tube formation in HUVEC cultures on matrix substrates;
• signalling readouts involving eNOS, VEGFR2 and focal adhesion kinase;
• protein and gene expression changes by western blot or quantitative PCR.

These assays describe cell behaviour in culture. They say nothing about an intact organism on their own.

Preclinical rodent models

Rodent models in the literature include tendon and ligament injury, skin wound models, and intestinal injury models. Reported readouts are mechanical and histological: tensile strength of repaired tissue, blinded or semi-quantitative histology scores, angiogenic marker density, and inflammatory cell counts in tissue sections. The published studies report compound amounts per experimental animal in controlled settings, with protocols that are not interchangeable between laboratories.

Tissue-repair findings in this literature come from cell cultures and animal models. They are laboratory observations, not descriptions of outcomes in people, and they are not a basis for human use.

Methodological criticism worth knowing

Parts of this literature have drawn criticism, and that criticism is itself part of the record. Common issues include small sample sizes, absent blinding in outcome assessment, wide variation in the amounts reported between studies, and limited independent replication. Reported amounts span more than an order of magnitude across nominally comparable papers, which makes direct comparison between them unreliable. Where an assay is subjective, such as a histology score, the absence of blinding is a material weakness rather than a technicality. A reader should treat individual reports as provisional until they are reproduced.

Handling and documentation

Both peptides are supplied as lyophilised powder for laboratory work. Purity, counter-ion form and storage conditions should be recorded with the experimental data, because they affect solubility and stability in assay buffers. Cold-chain insulated packaging and dispatch from South Africa apply to orders placed through our catalogue, including BPC-157 and TB-500. Orders placed before 11:00 SAST are processed the same day, nationwide courier is R250, and delivery is free on orders over R3,000. Catalogue and documentation questions can go to admin@skycorpeps.co.za or to WhatsApp on +27 78 350 0954.

Research use only. Not for human or veterinary consumption, diagnostic or therapeutic use.